Lipoprotein(a): A Lipoprotein Whose Time Has Come

Current Treatment Options in Cardiovascular Medicine
Erik Kelly, Linda Hemphill

Abstract

Cardiovascular disease is a leading cause of morbidity and mortality in the USA and around the world. While we are now able to achieve significant low-density lipoprotein cholesterol (LDL-C) lowering with current therapies, many patients remain at risk for cardiovascular disease (CVD). Elevated lipoprotein(a) [Lp(a)] has been shown to be an independent risk factor for CVD and accounts for some of the residual CVD risk after LDL-C lowering in several large clinical trials. Moreover, there is now strong evidence supporting the causal relationship between Lp(a) and aortic stenosis as well as peripheral arterial disease. Despite the growing interest in this lipoprotein, the current therapeutic options for Lp(a) reduction are limited. Our general approach in patients with elevated Lp(a) levels is to aggressively manage other modifiable cardiovascular risk factors including lifestyle modification, consideration of aspirin therapy, and LDL-C lowering. Unfortunately, there are conflicting reports on how effective this strategy is at reducing the risk for cardiovascular events attributed to elevated Lp(a). As a result, targeted Lp(a)-lowering strategies are needed. Lp(a) therapeutics is an active area of research with several promising ...Continue Reading

References

Dec 13, 1995·JAMA : the Journal of the American Medical Association·V M MaherJ J Albers
May 23, 1994·Archives of Internal Medicine·F M SacksB W Walsh
Feb 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·C J KimY K Min
Oct 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·R M LawnL Patthy
Dec 31, 1997·Medicine and Science in Sports and Exercise·L T MackinnonF Lepre
Jun 8, 2002·Atherosclerosis·Gérald LucUNKNOWN PRIME Study Group
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Jul 17, 2003·Current Opinion in Lipidology·Santica M Marcovina, Marlys L Koschinsky
Aug 9, 2003·The New England Journal of Medicine·JoAnn E MansonUNKNOWN Women's Health Initiative Investigators
Jul 8, 2005·The New England Journal of Medicine·Sotirios TsimikasPeter B Berger
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Jul 3, 2008·Journal of Lipid Research·Claes BergmarkSotirios Tsimikas
Feb 24, 2009·Nature Clinical Practice. Cardiovascular Medicine·Beate R JaegerUNKNOWN Group of Clinical Investigators
Jun 11, 2009·JAMA : the Journal of the American Medical Association·Pia R KamstrupBørge G Nordestgaard
Jul 23, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
May 8, 2010·Journal of the American College of Cardiology·Sebhat ErqouJohn Danesh
Jul 6, 2010·Journal of Lipid Research·Stephen J NichollsStanley L Hazen
Sep 11, 2010·Journal of the American College of Cardiology·Sotirios TsimikasS Matthijs Boekholdt
Oct 23, 2010·European Heart Journal·Børge G NordestgaardUNKNOWN European Atherosclerosis Society Consensus Panel
Nov 19, 2010·The New England Journal of Medicine·Christopher P CannonUNKNOWN Determining the Efficacy and Tolerability Investigators
Apr 9, 2011·Journal of the American College of Cardiology·Esther MerkiSotirios Tsimikas
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
May 26, 2012·Journal of Lipid Research·Kiyohito AraiSotirios Tsimikas
Oct 9, 2012·Current Opinion in Lipidology·Brian Kolski, Sotirios Tsimikas
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
Jan 11, 2013·International Journal of Rheumatology·I MissalaE Steinhagen-Thiessen
Feb 8, 2013·The New England Journal of Medicine·George ThanassoulisUNKNOWN CHARGE Extracoronary Calcium Working Group
Apr 25, 2013·Expert Opinion on Drug Safety·Kees HovinghJohn Kastelein

❮ Previous
Next ❯

Citations

Mar 16, 2019·Clinical Research in Cardiology Supplements·Norbert Weiss, Ulrich Julius
May 18, 2019·Current Medicinal Chemistry·Valentina ArnaoAntonio Pinto
Sep 25, 2019·Journal of Atherosclerosis and Thrombosis·Yuji Hirowatari, Hiroshi Yoshida
Nov 28, 2021·European Journal of Clinical Investigation·Amalia Despoina KoutsogianniAlexandros D Tselepis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.